Esperion Settles Investors' Cholesterol Drug Row For $18M
Investors in Esperion Therapeutics have notified a Michigan federal judge that they've reached an $18.25 million settlement deal with the company that would resolve claims it falsely stated regulators wouldn't be...To view the full article, register now.
Already a subscriber? Click here to view full article